{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:45:14Z","timestamp":1788547514149,"version":"build-2803163510"},"reference-count":191,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Dermatological vaccines have emerged as critical tools in preventing and managing a wide spectrum of skin conditions ranging from infectious diseases to malignancies. By synthesizing evidence from existing literature, this review aims to comprehensively evaluate the efficacy, safety, and immunogenicity of vaccines used in dermatology, including both approved vaccines and those currently being researched. Vaccines discussed in this paper include those targeting dermatoses and malignancies (e.g., acne vulgaris, atopic dermatitis, and melanoma); infectious diseases (e.g., human papillomavirus (HPV); varicella zoster virus (VZV); herpes zoster (HZ); warts; smallpox; mpox (monkeypox); hand, foot, and mouth disease (HFMD); candidiasis and Group B Streptococcus (GBS); and neglected tropical diseases (e.g., Buruli ulcer, leprosy, and leishmaniasis). Through this review, we aim to provide a detailed understanding of the role of vaccines in dermatology, identify knowledge gaps, and propose areas for future research.<\/jats:p>","DOI":"10.3390\/vaccines13020125","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T03:54:27Z","timestamp":1737950067000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vaccines in Dermatology\u2014Present and Future: A Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Eyan","family":"Goh","sequence":"first","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-541X","authenticated-orcid":false,"given":"Jean-Marc","family":"Chavatte","sequence":"additional","affiliation":[{"name":"National Public Health Laboratory, Singapore 308442, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6654-026X","authenticated-orcid":false,"given":"Raymond T. P.","family":"Lin","sequence":"additional","affiliation":[{"name":"National Public Health Laboratory, Singapore 308442, Singapore"},{"name":"National University Hospital Singapore, Singapore 119077, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4071-5222","authenticated-orcid":false,"given":"Lisa F. P.","family":"Ng","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore"},{"name":"A*STAR Infectious Diseases Labs (A*STAR IDL), Agency for Science, Technology, and Research (A*STAR), Singapore 138648, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"R\u00e9nia","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore"},{"name":"A*STAR Infectious Diseases Labs (A*STAR IDL), Agency for Science, Technology, and Research (A*STAR), Singapore 138648, Singapore"},{"name":"School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-3124","authenticated-orcid":false,"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore"},{"name":"National Skin Centre and Skin Research Institute of Singapore, Singapore 308205, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"ref_1","unstructured":"(2024, July 07). Vaccine-Preventable Diseases. Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1430","DOI":"10.1111\/jdv.19349","article-title":"A Call for Action to Tackle the Increasing Global Burden and Challenges of Acne","volume":"37","author":"Oon","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.19540","article-title":"Acne microbiome: From phyla to phylotypes","volume":"38","author":"Dreno","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"McLaughlin, J., Watterson, S., Layton, A.M., Bjourson, A.J., Barnard, E., and McDowell, A. (2019). Propionibacterium acnes and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies. Microorganisms, 7.","DOI":"10.3390\/microorganisms7050128"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mjd.2002.120912","article-title":"Acne Therapy: A Methodologic Review","volume":"47","author":"Lehmann","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","unstructured":"(2024, July 16). Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris. Clin. Trials Gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05131373."},{"key":"ref_7","unstructured":"(2024, July 16). Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults with Moderate to Severe Acne. Clin. Trials Gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06316297."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2017.04.017","article-title":"Identifying What to Measure in Acne Clinical Trials: First Steps Towards Development of a Core Outcome Set","volume":"137","author":"Layton","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1126\/science.1100330","article-title":"The complete genome sequence of Propionibacterium acnes, a commensal of human skin","volume":"305","author":"Bruggemann","year":"2004","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mayslich, C., Grange, P.A., and Dupin, N. (2021). Cutibacterium acnes as an Opportunistic Pathogen: An Update of Its Virulence-Associated Factors. Microorganisms, 9.","DOI":"10.3390\/microorganisms9020303"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/jid.2008.117","article-title":"Antibodies elicited by inactivated Propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: Relevance to therapy for acne vulgaris","volume":"128","author":"Nakatsuji","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3920\/BM2012.0062","article-title":"Bacterial skin commensals and their role as host guardians","volume":"5","author":"Christensen","year":"2014","journal-title":"Benef. Microbes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1551","DOI":"10.1371\/journal.pone.0001551","article-title":"Vaccination Targeting a Surface Sialidase of P. acnes: Implication for New Treatment of Acne Vulgaris","volume":"3","author":"Nakatsuji","year":"2008","journal-title":"PLoS ONE"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1099\/vir.0.81651-0","article-title":"Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus","volume":"87","author":"Winter","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.vaccine.2011.02.036","article-title":"Passive Immunoprotection Targeting a Secreted CAMP Factor of Propionibacterium acnes as a Novel Immunotherapeutic for Acne Vulgaris","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.1160354","article-title":"Targeting QseC Signaling and Virulence for Antibiotic Development","volume":"321","author":"Rasko","year":"2008","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jid.2018.05.032","article-title":"The Anti-Inflammatory Activities of Propionibacterium acnes CAMP Factor-Targeted Acne Vaccines","volume":"138","author":"Wang","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1038\/s41467-023-43833-8","article-title":"Functional divergence of a bacterial enzyme promotes healthy or acneic skin","volume":"14","author":"Hajam","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_19","first-page":"25.61","article-title":"Viral Infections","volume":"Volume 1","author":"Griffiths","year":"2004","journal-title":"Rook\u2019s Textbook of Dermatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3802\/jgo.2016.27.e21","article-title":"Clinical Significance of Human Papillomavirus Genotyping","volume":"27","author":"Choi","year":"2016","journal-title":"J. Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","article-title":"Significant Decrease in the Incidence of Genital Warts in Young Danish Women after Implementation of a National Human Papillomavirus Vaccination Program","volume":"40","author":"Baandrup","year":"2013","journal-title":"Sex. Transm. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/dc.24705","article-title":"The Meaning of High-Risk HPV Other Than Type 16\/18 in Women with Negative Cytology: Is It Really Safe to Wait for 1 Year?","volume":"49","author":"Kabaca","year":"2021","journal-title":"Diagn. Cytopathol."},{"key":"ref_23","first-page":"1710","article-title":"Warts (non-genital)","volume":"2014","author":"Loo","year":"2014","journal-title":"BMJ Clin. Evid."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.vaccine.2013.10.081","article-title":"HPV Vaccines to Prevent Cervical Cancer and Genital Warts: An Update","volume":"32","author":"Dochez","year":"2014","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human Papillomavirus Vaccines","volume":"224","author":"Markowitz","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"FUTURE II Study Group (2007). Quadrivalent Vaccine Against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N. Engl. J. Med., 356, 1915\u20131920.","DOI":"10.1056\/NEJMoa061741"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Luna, J., Plata, M., Gonzalez, M., Correa, A., Maldonado, I., Nossa, C., Radley, D., Vuocolo, S., Haupt, R.M., and Saah, A. (2013). Long-Term Follow-Up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil\u2122 in Adult Women. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083431"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained Efficacy Up to 4.5 Years of a Bivalent L1 Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18: Follow-Up from a Randomised Control Trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection with Human Papillomavirus Types 16 and 18 in Young Women: A Randomised Controlled Trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a Prophylactic Adjuvanted Bivalent L1 Virus-Like-Particle Vaccine Against Infection with Human Papillomavirus Types 16 and 18 in Young Women: An Interim Analysis of a Phase III Double-Blind, Randomised Controlled Trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall Efficacy of HPV-16\/18 AS04-Adjuvanted Vaccine Against Grade 3 or Greater Cervical Intraepithelial Neoplasia: 4-Year End-of-Study Analysis of the Randomised, Double-Blind PATRICIA Trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaad.2023.06.042","article-title":"Treatment Response and Tolerability of Intralesional Quadrivalent versus Bivalent Human Papillomavirus Vaccine for Recalcitrant Warts: A Randomized Controlled Trial","volume":"89","author":"Nofal","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.47102\/annals-acadmedsg.2020342","article-title":"The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Non-genital Warts: A Retrospective Study","volume":"49","author":"Kuan","year":"2020","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/bjd.18645","article-title":"Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) vaccine: The HPV type may not determine the outcome","volume":"182","author":"Hayashi","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_36","first-page":"540","article-title":"Efficacy and Safety of Intralesional Quadrivalent Human Papillomavirus Vaccine as Immunotherapy in Management of Recalcitrant Genital Warts in a Tertiary Health Care Centre of North India","volume":"11","author":"Kumar","year":"2021","journal-title":"Natl. J. Physiol. Pharm. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2019.07.070","article-title":"Intralesional Versus Intramuscular Bivalent Human Papillomavirus Vaccine in the Treatment of Recalcitrant Common Warts","volume":"82","author":"Nofal","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.amepre.2024.03.008","article-title":"Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination","volume":"67","author":"Song","year":"2024","journal-title":"Am. J. Prev. Med."},{"key":"ref_39","unstructured":"World Health Organization (2024, July 16). Human Papillomavirus Vaccines: WHO Position Paper (2022 Update). Wkly. Epidemiol. Rec., Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of Human Papillomavirus Vaccines: A Review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf."},{"key":"ref_41","unstructured":"Centers for Disease Control and Prevention (CDC) (2010). FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunisation Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep., 59, 626."},{"key":"ref_42","first-page":"268","article-title":"Human Papillomavirus Vaccine and Pregnancy","volume":"58","author":"Narducci","year":"2012","journal-title":"Can. Fam. Physician"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Patil, A., Goldust, M., and Wollina, U. (2022). Herpes zoster: A Review of Clinical Manifestations and Management. Viruses, 14.","DOI":"10.3390\/v14020192"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical Practice: Herpes Zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00128071-200506050-00005","article-title":"Current Management of Herpes Zoster: The European View","volume":"6","author":"Volpi","year":"2005","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/ITT.S176383","article-title":"Varicella zoster virus vaccines: An update","volume":"8","author":"Gabutti","year":"2019","journal-title":"ImmunoTargets and therapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medmal.2018.04.395","article-title":"Chickenpox: An Update","volume":"49","author":"Curti","year":"2019","journal-title":"Med. Mal. Infect."},{"key":"ref_49","first-page":"406","article-title":"Shingrix: A New Herpes Zoster Vaccine","volume":"44","author":"Maltz","year":"2019","journal-title":"P T."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.jvacx.2023.100397","article-title":"Efficacy and Safety of the Recombinant Zoster Vaccine: A Systematic Review and Meta-Analysis","volume":"15","author":"Zeevaert","year":"2023","journal-title":"Vaccine X"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apa.16136","article-title":"Randomised Controlled Trial Showed Long-Term Efficacy, Immunogenicity, and Safety of Varicella Vaccines in Norwegian and Swedish Children","volume":"111","author":"Casabona","year":"2022","journal-title":"Acta Paediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/INF.0b013e31829ae263","article-title":"The Effectiveness of Varicella Vaccination in Children in Germany: A Case-Control Study","volume":"32","author":"Liese","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3346\/jkms.2016.31.1.13","article-title":"Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX\u2122) in Korean Adults","volume":"31","author":"Choi","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_56","unstructured":"World Health Organisation (2024, July 16). Varicella and Herpes Zoster Vaccines: WHO Position Paper, June 2014. WHO, Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer-8925-265-288."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/archdischild-2018-314765","article-title":"Fifteen-minute consultation: Chickenpox vaccine-should parents immunise their children privately?","volume":"104","author":"Gray","year":"2019","journal-title":"Arch. Dis. Child. Educ. Pract. Ed."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/M15-3005","article-title":"Advisory Committee on Immunisation Practices. Advisory Committee on Immunisation Practices Recommended Immunisation Schedule for Adults Aged 19 Years or Older: United States","volume":"164","author":"Kim","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Macartney, K., Heywood, A., and McIntyre, P. Vaccines for Post-Exposure Prophylaxis Against Varicella (Chickenpox) in Children and Adults. Cochrane Database Syst. Rev., 2014.","DOI":"10.1002\/14651858.CD001833.pub3"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/21645515.2017.1388479","article-title":"Evaluation of Immunogenicity and Safety of VARIVAX\u2122 New Seed Process (NSP) in Children","volume":"14","author":"Senders","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1080\/21645515.2017.1318236","article-title":"Safety and Immunogenicity of Bio Pox\u2122, a Live Varicella Vaccine (Oka Strain) in Indian Children: A Comparative Multicentric, Randomized Phase II\/III Clinical Trial","volume":"13","author":"Dubey","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cmi.2018.12.033","article-title":"Efficacy, Safety, and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Children in China: Double-Blind, Randomized, Placebo-Controlled Clinical Trial","volume":"25","author":"Hao","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ohfuji, S., Ito, K., Inoue, M., Ishibashi, M., Kumashiro, H., Hirota, Y., Kayano, E., and Ota, N. (2019). Safety of Live Attenuated Varicella-Zoster Vaccine in Patients with Underlying Illnesses Compared with Healthy Adults: A Prospective Cohort Study. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3719-7"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.vaccine.2023.10.031","article-title":"Immunogenicity and Safety of a Live-Attenuated Varicella Vaccine in a Healthy Population Aged 13 Years and Older: A Randomized, Double-Blind, Controlled Study","volume":"42","author":"Huang","year":"2024","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.vaccine.2021.02.013","article-title":"Immunogenicity and Safety Profiles of a New MAV\/06 Strain Varicella Vaccine in Healthy Children: A Multinational, Multicenter, Randomized, Double-Blinded, Active-Controlled Phase III Study","volume":"39","author":"Choi","year":"2021","journal-title":"Vaccine"},{"key":"ref_66","unstructured":"Food and Drug Administration (2024, July 16). Shingrix [Package Insert], Available online: https:\/\/www.fda.gov\/media\/108597\/download."},{"key":"ref_67","first-page":"488","article-title":"Treatment of metastatic melanoma: An overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40425-019-0552-x","article-title":"Multiple Antigen-Engineered DC Vaccines with or without IFN\u03b1 to Promote Antitumor Immunity in Melanoma","volume":"7","author":"Butterfield","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/SLA.0000000000001419","article-title":"Long-Term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma","volume":"262","author":"Hu","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lugovi\u0107-Mihi\u0107, L., Me\u0161trovi\u0107-\u0160tefekov, J., Poto\u010dnjak, I., Cindri\u0107, T., Ili\u0107, I., Lovri\u0107, I., Skalicki, L., Be\u0161li\u0107, I., and Pondeljak, N. (2023). Atopic Dermatitis: Disease Features, Therapeutic Options, and a Multidisciplinary Approach. Life, 13.","DOI":"10.3390\/life13061419"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jid.2017.07.834","article-title":"Skin Colonization by Staphylococcus aureus Precedes the Clinical Diagnosis of Atopic Dermatitis in Infancy","volume":"137","author":"Meylan","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaci.2018.08.038","article-title":"Next-Generation Anti\u2013Staphylococcus aureus Vaccines: A Potential New Therapeutic Option for Atopic Dermatitis?","volume":"143","author":"Clowry","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bjd.16722","article-title":"The Widespread Use of Topical Antimicrobials Enriches for Resistance in Staphylococcus aureus Isolated from Atopic Dermatitis Patients","volume":"179","author":"Harkins","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"eaah4680","DOI":"10.1126\/scitranslmed.aah4680","article-title":"Antimicrobials from Human Skin Commensal Bacteria Protect Against Staphylococcus aureus and Are Deficient in Atopic Dermatitis","volume":"9","author":"Nakatsuji","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.vaccine.2017.01.024","article-title":"SA4Ag, a 4-Antigen Staphylococcus aureus Vaccine, Rapidly Induces High Levels of Bacteria-Killing Antibodies","volume":"35","author":"Begier","year":"2017","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/21645515.2017.1395540","article-title":"Safety of Staphylococcus aureus Four-Antigen and Three-Antigen Vaccines in Healthy Adults: A Meta-Analysis of Randomized Controlled Trials","volume":"14","author":"Xu","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ije\/dyp307","article-title":"Does BCG Vaccination Protect Against the Development of Childhood Asthma? A Systematic Review and Meta-Analysis of Epidemiological Studies","volume":"39","author":"Parent","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/archdischild-2013-305655","article-title":"Does Neonatal BCG Vaccination Prevent Allergic Disease in Later Life?","volume":"99","author":"Freyne","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaci.2010.07.039","article-title":"BCG Vaccination and Allergy: A Systematic Review and Meta-Analysis","volume":"127","author":"Arnoldussen","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0091-6749(98)70030-2","article-title":"BCG Infection Suppresses Allergic Sensitization and Development of Increased Airway Reactivity in an Animal Model","volume":"102","author":"Herz","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/trstmh\/tru196","article-title":"BCG-Associated Heterologous Immunity, a Historical Perspective: Experimental Models and Immunological Mechanisms","volume":"109","author":"Freyne","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/all.15022","article-title":"Prevention of Infant Eczema by Neonatal Bacillus Calmette-Gu\u00e9rin Vaccination: The MIS BAIR Randomized Controlled Trial","volume":"77","author":"Pittet","year":"2021","journal-title":"Allergy"},{"key":"ref_85","first-page":"498","article-title":"Neonatal BCG Vaccination and Atopic Dermatitis Before 13 Months of Age: A Randomized Clinical Trial","volume":"73","author":"Pihl","year":"2017","journal-title":"Allergy"},{"key":"ref_86","first-page":"892","article-title":"Therapeutic management of cutaneous and genital warts","volume":"14","author":"Ockenfels","year":"2016","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Al-Eitan, L.N., Alghamdi, M.A., Tarkhan, A.H., and Al-Qarqaz, F.A. (2020). Genome-wide identification of methylated CpG sites in nongenital cutaneous warts. BMC Med. Genom., 13.","DOI":"10.1186\/s12920-020-00745-6"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bjd.13310","article-title":"British Association of Dermatologists\u2019 guidelines for the management of cutaneous warts","volume":"171","author":"Sterling","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_89","first-page":"583","article-title":"The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study","volume":"315","author":"Shamma","year":"2023","journal-title":"Arch Dermatol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1203475421991130","article-title":"Intralesional Measles, Mumps, and Rubella Vaccine Versus Intralesional Candida Antigen in the Treatment of Common and Plantar Warts","volume":"25","author":"Nofal","year":"2021","journal-title":"J. Cutaneous Med. Surg."},{"key":"ref_91","first-page":"1","article-title":"Intralesional injection of Candida albicans antigen versus measles, mumps, and rubella vaccine for treatment of plantar warts","volume":"30","author":"Rageh","year":"2021","journal-title":"Acta Dermatovenerol. Alp Pannonica Adriat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/1203475420988859","article-title":"Intralesional antigen immunotherapy in the treatment of periungual warts","volume":"25","author":"Nofal","year":"2021","journal-title":"J. Cutaneous Med. Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/jocd.14737","article-title":"Comparative study between intralesional injection of MMR, BCG, and Candida albicans antigen in the treatment of multiple recalcitrant warts","volume":"21","author":"Eldahshan","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Talapko, J., Juzba\u0161i\u0107, M., Matijevi\u0107, T., Pustijanac, E., Beki\u0107, S., Kotris, I., and \u0160krlec, I. (2021). Candida albicans: The virulence factors and clinical manifestations of infection. J. Fungi, 7.","DOI":"10.3390\/jof7020079"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: A systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1477-7525-11-169","article-title":"Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA","volume":"11","author":"Guelfucci","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"657.e1","DOI":"10.1016\/j.ajog.2015.11.022","article-title":"Fluconazole use and birth defects in the National Birth Defects Prevention Study","volume":"214","author":"Howley","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/cid\/ciy185","article-title":"A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis\u2014A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial","volume":"66","author":"Edwards","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","unstructured":"World Health Organization (WHO) (2018). BCG vaccines: WHO position paper\u2014February 2018. Wkly Epidemiol Rec., 93, 73\u201396. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer9308-73-96."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Pluschke, G., and R\u00f6ltgen, K. (2019). Buruli Ulcer\u2014Mycobacterium Ulcerans Disease, Springer Nature.","DOI":"10.1007\/978-3-030-11114-4"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/21645515.2019.1706930","article-title":"BCG: A vaccine with multiple faces","volume":"16","author":"Unzueta","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.vaccine.2020.11.045","article-title":"Mycobacterium Ulcerans-Specific Immune Response after Immunisation with Bacillus Calmette-Gu\u00e9rin (BCG) Vaccine","volume":"39","author":"Pittet","year":"2020","journal-title":"Vaccine"},{"key":"ref_104","first-page":"1389","article-title":"Prophylactic Effect of Mycobacterium Bovis BCG Vaccination against Osteomyelitis in Children with Mycobacterium Ulcerans Disease (Buruli Ulcer)","volume":"9","author":"Portaels","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Phillips, R.O., Phanzu, D.M., Beissner, M., Badziklou, K., Luzolo, E.K., Sarfo, F.S., Halatoko, W.A., Amoako, Y., Frimpong, M., and Kabiru, A.M. (2015). Effectiveness of routine BCG vaccination on buruli ulcer disease: A case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003457"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Orujyan, D., Narinyan, W., Rangarajan, S., Rangchaikul, P., Prasad, C., Saviola, B., and Venketaraman, V. (2022). Protective efficacy of BCG vaccine against Mycobacterium leprae and non-tuberculous mycobacterial infections. Vaccines, 10.","DOI":"10.3390\/vaccines10030390"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1016\/j.vaccine.2019.08.067","article-title":"BCG Vaccine and Leprosy Household Contacts: Protective Effect and Probability to Becoming Sick during Follow-Up","volume":"37","author":"Gomes","year":"2019","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.4103\/jfmpc.jfmpc_478_20","article-title":"BCG Vaccination: Effects on the Patterns of Pediatric Leprosy","volume":"9","author":"Sarkar","year":"2020","journal-title":"J Family Med. Prim. Care."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/erv.09.161","article-title":"BCG vaccination and leprosy protection: Review of current evidence and status of BCG in leprosy control","volume":"9","author":"Merle","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijid.2016.10.018","article-title":"Novel Approaches to Tuberculosis Vaccine Development","volume":"56","author":"Kaufmann","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.abd.2020.08.032","article-title":"Chronic Recalcitrant Erythema Nodosum Leprosum: Therapeutic Dilemma and Role of Mycobacterium Indicus Pranii Vaccine","volume":"97","author":"Gupta","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-018-0050-z","article-title":"LepVax, a Defined Subunit Vaccine That Provides Effective Pre-Exposure and Post-Exposure Prophylaxis of M. Leprae Infection","volume":"3","author":"Duthie","year":"2018","journal-title":"npj Vaccines"},{"key":"ref_113","unstructured":"World Health Organisation (WHO) (2025, January 23). Leishmaniasis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: A Review","volume":"6","author":"Arenas","year":"2017","journal-title":"F1000Research"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/ijd.IJD_602_20","article-title":"Post Kala-Azar Dermal Leishmaniasis","volume":"66","author":"Kumar","year":"2021","journal-title":"Indian J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Knight, C.A., Harris, D.R., Alshammari, S.O., Gugssa, A., Young, T., and Lee, C.M. (2023). Leishmaniasis: Recent Epidemiological Studies in the Middle East. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1052478"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Osman, M., Mistry, A., Keding, A., Gabe, R., Cook, E., Forrester, S., Wiggins, R., Marco, S.D., Stefano, C., and Siani, L. (2017). A Third Generation Vaccine for Human Visceral Leishmaniasis and Post Kala Azar Dermal Leishmaniasis: First-In-Human Trial of ChAd63-KH. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005527"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1038\/s41467-020-17154-z","article-title":"A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Pacheco-Fernandez, T., Volpedo, G., Gannavaram, S., Bhattacharya, P., Dey, R., Abhay, S., Matlashewski, G., and Nakhasi, H.L. (2021). Revival of Leishmanization and Leishmanin. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.639801"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ayala, A., Llanes, A., Lleonart, R., and Restrepo, C.M. (2024). Advances in Leishmania Vaccines: Current Development and Future Prospects. Pathogens, 13.","DOI":"10.3390\/pathogens13090812"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/trstmh\/trt006","article-title":"Cluster Randomised Trial to Evaluate the Effectiveness of a Vaccine against Cutaneous Leishmaniasis in the Caratinga Microregion, South-East Brazil","volume":"107","author":"Mayrink","year":"2013","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bjd.12205","article-title":"Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India","volume":"168","author":"Bumb","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From Mouse to Man: Safety, Immunogenicity and Efficacy of a Candidate Leishmaniasis Vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1089\/hum.1998.9.13-1899","article-title":"Genetic Immunization with Glycoprotein 63 cDNA Results in a Helper T Cell Type 1 Immune Response and Protection in a Murine Model of Leishmaniasis","volume":"9","author":"Walker","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0264-410X(02)00769-7","article-title":"DNA Vaccines Induce Partial Protection against Leishmania mexicana","volume":"21","author":"Dumonteil","year":"2003","journal-title":"Vaccine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and Immunogenicity of ChAd63-KH Vaccine in Post-Kala-Azar Dermal Leishmaniasis Patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Rodrigo, A., Dias, D.S., Ribeiro, F., Roatt, B.M., Mas, A., Carri\u00f3n, J., and Dom\u00ednguez-Bernal, G. (2019). Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB\/c Mice. Vaccines, 7.","DOI":"10.3390\/vaccines7040183"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular Multiantigen T Cell Epitope\u2013Enriched DNA Vaccine against Human Leishmaniasis","volume":"6","author":"Das","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Qin, F., Xia, F., Chen, H., Cui, B., Feng, Y., Zhang, P., Chen, J., and Luo, M. (2021). A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications. Front. Cell. Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.633776"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3347\/kjp.2022.60.6.379","article-title":"Leishmania Vaccines: The Current Situation with Its Promising Aspect for the Future","volume":"60","author":"Dinc","year":"2022","journal-title":"Korean, J. Parasitol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Duthie, M.S., Hoeven, N.V., MacMillen, Z., Picone, A., Mohamath, R., Erasmus, J., Hsu, F.-C., Stinchcomb, D.T., and Reed, S.G. (2018). Heterologous Immunization with Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect against Leishmania Donovani. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02420"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Lafleur, A., Daffis, S., Mowbray, C., and Arana, B. (2024). Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis. Vaccines, 12.","DOI":"10.3390\/vaccines12101179"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"104117","DOI":"10.1016\/j.lpm.2022.104117","article-title":"Life and Death of Smallpox","volume":"51","author":"Berche","year":"2022","journal-title":"Presse. M\u00e9d."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox Vaccines: Past, Present, and Future","volume":"118","author":"Parrino","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"118","DOI":"10.46234\/ccdcw2024.025","article-title":"The Current State and Progress of Mpox Vaccine Research","volume":"6","author":"Wang","year":"2024","journal-title":"China CDC Wkly."},{"key":"ref_137","unstructured":"(2025, January 14). CDC: About Smallpox Vaccines, Available online: https:\/\/www.cdc.gov\/smallpox\/hcp\/vaccines\/index.html."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II Randomized, Double-Blinded Comparison of a Single High Dose (5\u00d7108 TCID50) of Modified Vaccinia Ankara Compared to a Standard Dose (1 \u00d7 108 TCID50) in Healthy Vaccinia-Na\u00efve Individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara as a Smallpox Vaccine in People with Atopic Dermatitis","volume":"32","author":"Perona","year":"2014","journal-title":"Vaccine"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and Immunogenicity of IMVAMUNE\u00ae Smallpox Vaccine Using Different Strategies for a Post Event Scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1016\/j.vaccine.2013.08.071","article-title":"An Open-Label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Adults","volume":"31","author":"Kim","year":"2013","journal-title":"Vaccine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: An Attenuated Smallpox Vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","article-title":"A Randomized Phase II Trial to Compare Safety and Immunogenicity of the MVA-BN Smallpox Vaccine at Various Doses in Adults with a History of AIDS","volume":"38","author":"Overton","year":"2020","journal-title":"Vaccine"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.291.6.725","article-title":"Tertiary Contact Vaccinia in a Breastfeeding Infant","volume":"291","author":"Garde","year":"2004","journal-title":"JAMA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12519-022-00630-5","article-title":"Monkeypox and the perinatal period: What does maternal-fetal medicine need to know?","volume":"19","author":"Yan","year":"2023","journal-title":"World J. Pediatr."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Fern\u00e1ndez, D.E., Fern\u00e1ndez-Quezada, D., Antonio, F., Carrillo-Ballesteros, F.J., Ortega-Prieto, A.M., Jimenez-Guarde\u00f1o, J.M., and Regla-Nava, J.A. (2023). Human Monkeypox: A Comprehensive Overview of Epidemiology, Pathogenesis, Diagnosis, Treatment, and Prevention Strategies. Pathogens, 12.","DOI":"10.3390\/pathogens12070947"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamadermatol.2023.0041","article-title":"Mpox\u2014A Rapidly Evolving Disease","volume":"159","author":"Cowen","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S1473-3099(22)00574-6","article-title":"Prevention of monkeypox with vaccines: A rapid review","volume":"22","author":"Poland","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41392-023-01574-6","article-title":"Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/ije\/17.3.643","article-title":"The transmission potential of monkeypox virus in human populations","volume":"17","author":"Fine","year":"1988","journal-title":"Int. J. Epidemiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(23)00057-9","article-title":"Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: An observational study","volume":"23","author":"Bertran","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_155","first-page":"2200883","article-title":"Post-exposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022","volume":"28","author":"Morales","year":"2023","journal-title":"Euro. Surveill."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yang, K., and Zhou, H. (2023). Immunogenic Proteins and Potential Delivery Platforms for Mpox Virus Vaccine Development: A Rapid Review. Int. J. Biol. Macromol., 245.","DOI":"10.1016\/j.ijbiomac.2023.125515"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e0150421","DOI":"10.1128\/JVI.01504-21","article-title":"A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge","volume":"96","author":"Mucker","year":"2022","journal-title":"J. Virol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","article-title":"Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies","volume":"26","author":"Golden","year":"2008","journal-title":"Vaccine"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41422-023-00792-5","article-title":"Polyvalent MRNA Vaccination Elicited Potent Immune Response to Monkeypox Virus Surface Antigens","volume":"33","author":"Fang","year":"2023","journal-title":"Cell Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s11427-023-2378-x","article-title":"Multi-Valent MRNA Vaccines against Monkeypox Enveloped or Mature Viron Surface Antigens Demonstrate Robust Immune Response and Neutralizing Activity","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A Protein-Based Smallpox Vaccine Protects Mice from Vaccinia and Ectromelia Virus Challenges When given as a Prime and Single Boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Zhu, P., Ji, W., Li, D., Li, Z., Chen, Y., Dai, B., Han, S., Chen, S., Jin, Y., and Duan, G. (2023). Current Status of Hand-Foot-And-Mouth Disease. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00908-4"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An Inactivated Enterovirus 71 Vaccine in Healthy Children","volume":"370","author":"Li","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/14760584.2016.1096782","article-title":"Two-Year Efficacy and Immunogenicity of Sinovac Enterovirus 71 Vaccine against Hand, Foot and Mouth Disease in Children","volume":"15","author":"Li","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/cid\/ciz1114","article-title":"Effectiveness and Safety of an Inactivated Enterovirus 71 Vaccine in Children Aged 6\u201371 Months in a Phase IV Study","volume":"71","author":"Guan","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1115934","article-title":"Comprehensive Safety Assessment of a Human Inactivated Diploid Enterovirus 71 Vaccine Based on a Phase III Clinical Trial","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1016\/j.vaccine.2018.09.069","article-title":"Characterization of an Inactivated Whole-Virus Bivalent Vaccine That Induces Balanced Protective Immunity against Coxsackievirus A6 and A10 in Mice","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3390\/v7112916","article-title":"Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice","volume":"7","author":"Caine","year":"2015","journal-title":"Viruses"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2018.05.005","article-title":"The Immunogenicity and Protection Effect of an Inactivated Coxsackievirus A6, A10, and A16 Vaccine against Hand, Foot, and Mouth Disease","volume":"36","author":"Lim","year":"2018","journal-title":"Vaccine"},{"key":"ref_171","first-page":"1","article-title":"A Virus-like Particle-Based Tetravalent Vaccine for Hand, Foot, and Mouth Disease Elicits Broad and Balanced Protective Immunity","volume":"7","author":"Zhang","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12250-020-00294-3","article-title":"From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies against Hand, Foot, and Mouth Disease (HFMD)","volume":"36","author":"He","year":"2020","journal-title":"Virol. Sin."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Anasir, M.I., and Poh, C.L. (2019). Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061256"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17460441.2021.1965987","article-title":"Novel Strategies for the Development of Hand, Foot, and Mouth Disease Vaccines and Antiviral Therapies","volume":"17","author":"Fang","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s15010-007-7251-0","article-title":"Invasive Group B Streptococcal Disease in Non-Pregnant Adults","volume":"36","author":"Sendi","year":"2008","journal-title":"Infection"},{"key":"ref_176","unstructured":"Ikebe, T., Okuno, R., Uchitani, Y., Takano, M., Yamaguchi, T., Otsuka, H., Kazawa, Y., Fujita, S., Kobayashi, A., and Date, Y. (2023). Working Group for Beta-Hemolytic Streptococci in Japan. Serotype Distribution and Antimicrobial Resistance of Streptococcus agalactiae Isolates in Nonpregnant Adults with Streptococcal Toxic Shock Syndrome in Japan in 2014 to 2021. Microbiol. Spectr., 11."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.GPP3-0007-2018","article-title":"Group B Streptococcus (Streptococcus Agalactiae)","volume":"7","author":"Raabe","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Hasso-Agopsowicz, M., Hwang, A., Hollm-Delgado, M.G., Umbelino-Walker, I., Karron, R.A., Rao, R., Asante, K.P., Sheel, M., Sparrow, E., and Giersing, B. (2024). Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): An objective of the Immunization Agenda 2030. EBioMedicine, 110.","DOI":"10.1016\/j.ebiom.2024.105424"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children","volume":"65","author":"Seale","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1473-3099(16)00152-3","article-title":"Safety and Immunogenicity of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Healthy Women and Their Infants: A Randomised Phase 1b\/2 Trial","volume":"16","author":"Madhi","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.vaccine.2020.02.085","article-title":"Safety and Immunogenicity of Fully Liquid and Lyophilized Formulations of an Investigational Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women: Results from a Randomized Comparative Phase II Trial","volume":"38","author":"Beran","year":"2020","journal-title":"Vaccine"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1016\/j.vaccine.2020.08.056","article-title":"Safety and Immunogenicity of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Pregnant Women and Their Infants: Results from a Randomized Placebo-Controlled Phase II Trial","volume":"38","author":"Swamy","year":"2020","journal-title":"Vaccine"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/AOG.0000000000001190","article-title":"Maternal Immunization with an Investigational Trivalent Group B Streptococcal Vaccine","volume":"127","author":"Donders","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jinf.2018.01.006","article-title":"Functional Activity of Maternal and Cord Antibodies Elicited by an Investigational Group B Streptococcus Trivalent Glycoconjugate Vaccine in Pregnant Women","volume":"76","author":"Fabbrini","year":"2018","journal-title":"J. Infect."},{"key":"ref_185","first-page":"2570","article-title":"Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4\u20136 Years after a First Dose: Results from a Phase 2 Trial","volume":"70","author":"Bebia","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(15)00484-3","article-title":"Group B Streptococcus Vaccination in Pregnant Women with or without HIV in Africa: A Non-Randomised Phase 2, Open-Label, Multicentre Trial","volume":"16","author":"Heyderman","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1473-3099(20)30478-3","article-title":"Safety and Immunogenicity of a Novel Hexavalent Group B Streptococcus Conjugate Vaccine in Healthy, Non-Pregnant Adults: A Phase 1\/2, Randomised, Placebo-Controlled, Observer-Blinded, Dose-Escalation Trial","volume":"21","author":"Absalon","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa2116045","article-title":"Potential for Maternally Administered Vaccine for Infant Group B Streptococcus","volume":"389","author":"Madhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1016\/j.vaccine.2021.06.046","article-title":"Safety and Immunogenicity of a Prototype Recombinant Alpha-like Protein Subunit Vaccine (GBS-NN) against Group B Streptococcus in a Randomised Placebo-Controlled Double-Blind Phase 1 Trial in Healthy Adult Women","volume":"39","author":"Fischer","year":"2021","journal-title":"Vaccine"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.fsi.2014.02.017","article-title":"Safety and Immunogenicity of an Oral DNA Vaccine Encoding Sip of Streptococcus Agalactiae from Nile Tilapia Oreochromis Niloticus Delivered by Live Attenuated Salmonella Typhimurium","volume":"38","author":"Huang","year":"2014","journal-title":"Fish Shellfish Immunol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/cid\/ciy838","article-title":"A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization with GBS III","volume":"68","author":"Hillier","year":"2018","journal-title":"Clin. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:25Z","timestamp":1759919785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":191,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["vaccines13020125"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13020125","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}